Literature DB >> 9700586

Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study.

M R Cardillo1, E Petrangeli, N Aliotta, L Salvatori, L Ravenna, C Chang, G Castagna.   

Abstract

The expression and distribution of androgen, estrogen and progesterone receptors was examined by immunohistochemical staining in 31 paraffin-embedded sections from ovarian tumors and the results were assessed by semiquantitative image analysis. Immunohistochemical staining showed heterogeneous patterns of steroid receptor distribution, with mainly nuclear immunoreactivity. Eighty-four percent of benign and malignant ovarian tumors expressed androgen receptors (AR), 74.19% estrogen receptors (ER) and 41.16% progesterone receptors (PR). All benign tumors showed immunoreactivity for the three steroid receptors. Malignant tumors expressed higher AR and ER histochemical scores (H-scores) than PR (82% vs 71% vs 39%). The incidence and expression levels of the steroid receptors varied widely in the different histological types of malignant tumors. Spearman rank analysis showed a positive significant (P < 0.05) correlation between AR- and ER and between ER- and PR-H-scores. In malignant ovarian tumors, neither AR, ER nor PR immunohistochemical scores correlated with tumor FIGO stage. Densitrometric analysis of immunostained steroid receptors is a valid method for assessing the steroid status, because it reduces subjective elements in scoring sections and increases the reliability of results. The high incidence of AR expression confirms the functional role of AR in ovarian tumors and suggests that the determination of AR content in ovarian cancer could have prognostic value.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700586

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  16 in total

1.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

2.  Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Authors:  Beryl L Manning-Geist; Sushmita B Gordhandas; Dilip D Giri; Alexia Iasonos; Qin Zhou; Jeffrey Girshman; Roisin E O'Cearbhaill; Dmitriy Zamarin; Stuart M Lichtman; Paul J Sabbatini; William P Tew; Karen Li; Autumn S McDonnell; Emeline M Aviki; Dennis S Chi; Carol A Aghajanian; Rachel N Grisham
Journal:  Gynecol Oncol       Date:  2021-11-08       Impact factor: 5.304

3.  Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.

Authors:  Björn Nodin; Nooreldin Zendehrokh; Jenny Brändstedt; Elise Nilsson; Jonas Manjer; Donal J Brennan; Karin Jirström
Journal:  J Ovarian Res       Date:  2010-06-17       Impact factor: 4.234

4.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

5.  Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer.

Authors:  Xinyu Wu; Yang Zhan; Xin Li; Jianjun Wei; Larion Santiago; Garrett Daniels; Fangming Deng; Xuelin Zhong; Luis Chiriboga; Ross Basch; Sheng Xiong; Yan Dong; Xinmin Zhang; Peng Lee
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

6.  Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.

Authors:  Fengkun Du; Yan Li; Wensheng Zhang; Shubha P Kale; Harris McFerrin; Ian Davenport; Guangdi Wang; Elena Skripnikova; Xiao-Lin Li; Nathan J Bowen; Leticia B McDaniels; Yuan-Xiang Meng; Paula Polk; Yong-Yu Liu; Qian-Jin Zhang
Journal:  Tumour Biol       Date:  2016-03-02

7.  Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer.

Authors:  Martin Ligr; Ruzeen Rohintan Patwa; Garrett Daniels; Lorraine Pan; Xinyu Wu; Yirong Li; Liantian Tian; Zhenxing Wang; Ruliang Xu; Jingjing Wu; Fan Chen; Jinsong Liu; Jian-Jun Wei; Peng Lee
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

8.  Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study.

Authors:  Pooja S Naik; Sanjay Deshmukh; Siddhi Gaurish Sinai Khandeparkar; Avinash Joshi; Shridhar Babanagare; Jyostna Potdar; Neelesh Sharad Risbud
Journal:  J Midlife Health       Date:  2015 Oct-Dec

Review 9.  AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  Cancers (Basel)       Date:  2017-01-11       Impact factor: 6.639

10.  Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.

Authors:  Jenny-Maria Jönsson; Nicolai Skovbjerg Arildsen; Susanne Malander; Anna Måsbäck; Linda Hartman; Mef Nilbert; Ingrid Hedenfalk
Journal:  Transl Oncol       Date:  2015-10       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.